Since its approval, BiDil has not been a great commercial success but it remains on the market.

FORBES: Don't Let Political Correctness Compromise Medical Care

In November, a tiny company called NitroMed unveiled results showing that its drug combo, BiDil, reduced deaths due to heart failure by half.

FORBES: Magazine Article

Previously, BiDil had never been a true success in clinical trials containing both whites and blacks, but seemed to work well in African-Americans.

FORBES: Race-Based Medicine, Genomics And You

On top of the best treatments available, BiDil still increased survival of African-American heart failure patients by 43% compared with a sugar pill, while cutting hospitalizations by 33%.

FORBES: Race-Based Medicine, Genomics And You